In addition, as in cell culture anti-EGFR treatment was proved effective for a subset of ameloblastomas (i.e. those BRAF wild-type) [1, 24], our findings bring to light a possible resistance mechanism to anti-EGFR therapy in such tumors, as shown for other neoplasms. This evidence concerns the gene EGFR and neoplasm.